Pyruvate kinase activators for use in treating blood disorders

Patent metadata

Field	Value
Publication number	US-11590132-B2
Application number	US-201816639081-A
Country	US
Kind code	B2
Filing date	Aug 15, 2018
Priority date	Aug 15, 2017
Publication date	Feb 28, 2023
Grant date	Feb 28, 2023

Abstract

Described herein are compounds that activate pyruvate kinase, pharmaceutical compositions and methods of use thereof. These compounds are represented by Formula (I) wherein R 1 , R 2 , R a , R b , R j , R k , and Q are as defined herein.

First claim

The invention claimed is:

1. A compound represented by the following structural formula:

or a pharmaceutically acceptable salt thereof, wherein:
R 1 is hydrogen, an optionally substituted alkyl, an optionally substituted haloalkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted heterocyclyl, an optionally substituted aryl, —OR o1 , —C(═O)R c1 , or a nitrogen protecting group; wherein:
R o1 is hydrogen, optionally substituted alkyl, or an oxygen protecting group;
R c1 is optionally substituted alkyl or —N(R cn ) 2 , wherein each instance of R cn is independently hydrogen, —C 1-6 alkyl, or a nitrogen protecting group;

R 2 and Q are each independently an optionally substituted 5- or 6-membered monocyclic heteroaryl;
R a and R b are each independently hydrogen, a halogen, —CN, —NO 2 ,—N 3 , an optionally substituted alkyl, —OR o3 , —N(R n1 ) 2 , —C(═O)N(R n1 ) 2 , or —C(═O)R c2 ; or alternatively R a and R b can be taken together with the carbon atom to which they are attached to form an optionally substituted cycloalkyl or an optionally substituted heterocyclyl; wherein:
each instance of R n1 is independently hydrogen, an optionally substituted —C 1 -C 6 alkyl, or a nitrogen protecting group;
R o3 is hydrogen, an optionally substituted —C 1 -C 6 alkyl, or an oxygen protecting group; and
R c2 is an optionally substituted —C 1 -C 6 alkyl; and

R j and R k are each independently hydrogen, a halogen, —CN, —OR o7 , —N(Rn 5 ) 2 , —N(R n5 )C(═O)R c5 , —C(═O)N(R n5 ) 2 , —C(═O)R c5 , —C(═O)OR o7 , —SR js , —S(═O) 2 R js , —S(═O)R js , or an optionally substituted —C 1 -C 6 alkyl; or alternatively R j and R k can be taken together with the carbon atom to which they are attached to form C═O, an optionally substituted C 1 -C 6 monocyclic cycloalkyl ring, or an optionally substituted C 3 -C 6 monocyclic heterocyclyl ring; wherein:
each instance of R n5 is independently hydrogen, an optionally substituted —C 1 -C 6 alkyl, —OR o8 , or a nitrogen protecting group, wherein R o8 is hydrogen, an optionally substituted —C 1 -C 6 alkyl, or an oxygen protecting group;
each instance of R o7 is independently hydrogen, an optionally substituted —C 1 -C 6 alkyl, or an oxygen protecting group;
each instance of R c5 is independently an optionally substituted —C 1 -C 6 alkyl; and
each instance of R js is independently an optionally substituted —C 1 -C 6 alkyl, an optionally substituted C 6-12 aryl, an optionally substituted heteroaryl, or a sulfur protecting group.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the 5- or 6-membered monocyclic heteroaryl represented by R 2 is optionally substituted at each substitutable ring carbon atom by R p and optionally substituted at each substitutable ring nitrogen atom by R n6 ; wherein:
each instance of R p is independently hydrogen, a halogen, —CN, —NO 2 , —N 3 , an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heterocyclyl, an optionally substituted heteroaryl, —OR o6 , —SR s2 , —N(R n3 ) 2 , —C(═O)N(R n3 ) 2 , —N(R n3 )C(═O)R c4 , —C(═O)R c4 , —C(═O)OR o6 , —OC(═O)R c4 , —S(═O)R s2 , —S(═O) 2 R s2 , —S(═O)OR o6 , —OS(═O)R c4 , —S(═O) 2 R o6 , —OS(═O) 2 R c4 , —S(═O)N(R n3 ) 2 , —S(═O) 2 N(R n3 ) 2 , —N(R n3 )S(═O)R s2 , —N(R n3 )S(═O) 2 R s2 , —N(R n3 )C(═O)OR o6 , —OC(═O)N(R n3 ) 2 , —N(R n3 )C(═O)N(R n3 ) 2 , —N(R n3 )S(═O)N(R n3 ) 2 , —N(R n3 )S(═O) 2 N(R n3 ) 2 , —N(R n3 )S(═O)OR o6 , —N(R′)S(═O) 2 OR o6 , —OS(═O)N(R n3 ) 2 , or —OS(═O) 2 N(R n3 ) 2 ; or alternatively two instances of R p attached to the same or adjacent carbon atoms, can be taken together with the carbon atom(s) to which they are attached to form an optionally substituted cycloalkyl or a heterocycloalkyl; wherein:
each instance of R n3 is independently hydrogen, an optionally substituted —C 1 -C 6 alkyl, or a nitrogen protecting group;
each instance of R o6 is independently hydrogen, an optionally substituted —C 1 -C 6 alkyl, or an oxygen protecting group; and
each instance of R c4 is an optionally substituted —C 1 -C 6 alkyl;
each instance of R s2 is independently an optionally substituted —C 1 -C 6 alkyl or a sulfur protecting group; and

R n6 is hydrogen, an optionally substituted —C 1 -C 6 alkyl, or a nitrogen protecting group.

3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the 5- or 6-membered monocyclic heteroaryl represented by R 2 is selected from one of the following:

wherein:
each instance of R nc and R nd is independently hydrogen, optionally substituted —C 1 -C 6 alkyl, or a nitrogen protecting group; and
p is 0, 1, 2, 3, or 4, as valency permits.

4. The compound according to claim 3 or a pharmaceutically acceptable salt thereof, wherein each instance of R p is independently hydrogen, halogen, optionally substituted C 1-4 alkyl, —CN, —NO 2 , —N 3 , —OR o4 , —N(R n2 ) 2 , —C(═O)N(R n2 ) 2 , —C(═O)R c3 , or —C(═O)OR o4 .

5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the 5- or 6-membered monocyclic heteroaryl represented by Q is selected from the following:

wherein:
each instance of R n is independently hydrogen, a halogen, —CN, —NO 2 , —N 3 , an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heterocyclyl, an optionally substituted heteroaryl, —OR 4 , —SR s1 , —N(R n2 ) 2 , —C(═O)N(R n2 ) 2 , —N(R n2 )C(═O)R c3 , —C(═O)R c3 , —C(═O)OR o4 , —OC(═O)R c3 , —S(═O)R s1 , —S(═O) 2 R s1 , —S(═O)OR o4 , —OS(═O)R c3 , —S(═O) 2 OR o4 , —OS(═O) 2 R c3 , —S(═O)N(R n2 ) 2 , —S(═O) 2 N(R n2 ) 2 , —N(R n2 )S(═O)R s1 , —N(R n2 )S(═O) 2 R s1 , —N(R n2 )C(═O)OR o4 , —OC(═O)N(R n2 ) 2 , —N(R n2 )C(═O)N(R n2 ) 2 , —N(R n2 )S(═O)N(R n2 ) 2 , —N(R n2 )S(═O) 2 N(R n2 ) 2 , —N(R n2 )S(═O)OR o4 , —N(R n2 )S(═O) 2 OR o4 , —OS(═O)N(R n2 ) 2 , or —OS(═O) 2 N(R n2 ) 2 ; or two instances of R n attached to the same or adjacent carbon atoms, taken together with the carbon atoms to which they are attached to form an optionally substituted cycloalkyl or a heterocycloalkyl; wherein:
each instance of R n2 is independently hydrogen, an optionally substituted —C 1 -C 6 alkyl, or a nitrogen protecting group;
each instance of R o4 is independently hydrogen, an optionally substituted —C 1 -C 6 alkyl, or an oxygen protecting group;
each instance of R c3 is independently an optionally substituted —C 1 -C 6 alkyl;
each instance of R s1 is independently an optionally substituted —C 1 -C 6 alkyl or a sulfur protecting group;
n is 0, 1, 2, or 3, as valency permits; and
each of R na , R nb , and R nd is independently hydrogen, an optionally substituted —C 1 -C 6 alkyl, or a nitrogen protecting group.

6. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the 5- or 6-membered monocyclic heteroaryl represented by Q is

7. The compound according to claim 5 or a pharmaceutically acceptable salt thereof, wherein each instance of R n is independently hydr

Assignees

• Agios Pharmaceuticals Inc

Inventors

• Cianchetta Giovanni
• Liu Tao
• Padyana Anil Kumar
• Sui Zhihua
• Cai Zhenwei
• Cui Dawei
• Ji Jingjing

Classifications

• A61P7/06

  Antianaemics · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/506

  not condensed and containing further heterocyclic rings · CPC title

• C07D513/14 Primary

  Ortho-condensed systems · CPC title

• A61P35/00

  Antineoplastic agents · CPC title